Nilotinib
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Nilotinib: From Chronic Myeloid Leukaemia to Dermatofibrosarcoma Protuberans
One-Sentence Summary
Nilotinib (DrugBank DB04868) is a second-generation BCR-ABL tyrosine kinase inhibitor originally developed for chronic myeloid leukaemia (CML). The TxGNN model predicts it may be effective for dermatofibrosarcoma protuberans (DFSP), but this direction is currently supported by 0 clinical trials and only 1 mechanistic review article — the evidence base is thin and largely theoretical at this stage.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Chronic myeloid leukaemia (CML) — based on well-established public information; the evidence pack itself has no structured original-indication data (data gap) |
| Predicted New Indication | Dermatofibrosarcoma protuberans |
| TxGNN Prediction Score | 99.31% |
| Evidence Level | L4 |
| Australia Market Status | Not marketed (未上市) |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for nilotinib is not available in this evidence pack (data gap, DG002). Based on known public information, nilotinib is a second-generation BCR-ABL tyrosine kinase inhibitor used for chronic myeloid leukaemia, and it also inhibits PDGFR (both PDGFRA and PDGFRB) and KIT kinases as off-target activity within the same structural class as imatinib.
Dermatofibrosarcoma protuberans is typically driven by a COL1A1-PDGFB fusion gene, which causes constitutive activation of PDGFRB signalling. Imatinib — a drug with a very similar kinase-inhibition profile to nilotinib — is already approved for this indication. This provides a plausible mechanistic rationale for nilotinib: since it shares PDGFR-inhibitory activity with imatinib, it is reasonable to hypothesise similar activity in PDGFR-driven tumours such as DFSP.
However, this rationale is currently extrapolated from imatinib’s class effect and general PDGFR pharmacology rather than from any nilotinib-specific study in DFSP. No dedicated nilotinib clinical trial or case series in DFSP was identified.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 29408302 | 2018 | Review | Pharmacological Research | Reviews the role of small-molecule PDGFR inhibitors (as a class) in neoplastic disease; provides mechanistic background for PDGFR blockade in PDGFR-driven tumours but does not report nilotinib-specific efficacy data in DFSP |
Safety Considerations
No local safety data is available for nilotinib in this evidence pack. Key warnings, contraindications, and drug interaction data are all flagged as a blocking data gap (DG001) — TFDA label warnings/contraindications could not be retrieved, which means a formal safety pre-assessment (S1) cannot currently be completed. Please refer to the officially approved Product Information (PI) from a jurisdiction where nilotinib is marketed (e.g. FDA, EMA) for interim safety guidance until local label data is obtained.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked predicted indication (DFSP) has no clinical trial evidence and only one non-disease-specific mechanistic review (evidence level L4). Combined with the drug’s current unmarketed status locally (0 ARTG/license entries) and a blocking safety data gap, there is not yet enough evidence to proceed past the research-question stage.
To proceed, the following is needed:
- Resolve DG001 (blocking): obtain TFDA/PI warnings and contraindications before any safety pre-assessment
- Resolve DG002: confirm nilotinib’s MOA via DrugBank API to firm up the mechanistic rationale
- Nilotinib-specific preclinical or case-report data in DFSP, since current support is inferred from the imatinib class effect
- Consider that liposarcoma (rank 2) is a more evidence-mature candidate — it has an actual Phase I/II trial (GEIS-27, NCT02587169) and a related Phase I publication (evidence level L3, decision stage S2) — and may warrant parallel or prioritised review over DFSP
Other TxGNN-Predicted Indications (Overview)
For context, this evidence pack contains 10 candidate indications for nilotinib. Only the top-ranked one is detailed above per report scope; the remainder are summarised here for awareness:
| Rank | Predicted Indication | TxGNN Score | Evidence Level | Decision Stage | Recommendation | |——|———————-|————-|—————–|—————–|—————–| | 1 | Dermatofibrosarcoma protuberans | 99.31% | L4 | S1 | Research Question | | 2 | Liposarcoma | 98.85% | L3 | S2 | Research Question | | 3 | Ovarian myxoid liposarcoma | 98.74% | L5 | S0 | Hold | | 4 | Ewing sarcoma | 98.45% | L5 | S0 | Hold | | 5 | Ganglioneuroblastoma (disease) | 97.02% | L5 | S0 | Hold | | 6 | Heart fibrosarcoma | 97.01% | L5 | S0 | Hold | | 7 | Vertebral anomalies and variable endocrine and T-cell dysfunction | 96.94% | L5 | S0 | Hold (likely a KG entity-mapping artefact — recommend verifying entity validity before any further review) | | 8 | Kidney fibrosarcoma | 96.90% | L5 | S0 | Hold | | 9 | Fibroblastic neoplasm | 96.90% | L4 | S1 | Research Question | | 10 | Conventional fibrosarcoma | 96.79% | L5 | S0 | Hold |
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.